Business Wire

Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis

Share

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis.

“DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.”

The randomized, single-center, double-blind, vehicle-controlled Phase 1b/2a trial at the Centre of Human Disease Research (CHDR), Leiden, The Netherlands, is designed to evaluate the safety and efficacy profile of two dose strengths of DLQ02 and its vehicle in patients diagnosed with mild to moderate plaque psoriasis. A targeted total of 36 patients, 12 per treatment group, will be enrolled. Trial completion is expected in Q2 2023.

“DLQ02 is the first of three clinical trials in dermatology we are initiating in 2022, “said Frank Loescher, PhD, CEO & President of Dermaliq. “This is a significant step towards Dermaliq's goal of developing a new generation of superior topical drug therapies and medical skin care products. We can progress rapidly from preclinical to clinical stage building on our comprehensive safety and manufacturing experience with the hyliQTM technology. Based on the same technology (EyeSol® from Novaliq), two ophthalmology products for the treatment of Dry Eye Disease (CyclASol, NOV03), are currently in registration with New Drug Applications (NDAs) submitted to FDA”

About DLQ02

DLQ02 is a liquid topical, calcineurin inhibitor with anti-inflammatory and immunomodulating properties, developed for the treatment of Psoriasis. There remains an unmet need for topical therapies, particularly for localized lesions only affecting limited body surface areas, which are usually not eligible for systemic treatments. DLQ02 has the potential to provide a highly effective and safe treatment option.

About Dermaliq:

Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical Delaware corporation founded in 2021 through a spin off from Novaliq GmbH to reimagine topical dermatology.

Dermaliq’s mission is to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The unique “hyliQTM” technology is driving a growing product pipeline in key dermatological indications. We expect that the hyliQTM technology will offer superior bioavailability, stability and cosmetic acceptability as compared to currently marketed products.

Earlier this year, Dermaliq secured USD 15 million in a series A round to advance the development of three transformative skin care drug therapies including DLQ02. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.

Forward-Looking Disclosures:

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. The information contained in this release is as of August 18, 2022. Dermaliq assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a potential topical treatment for psoriasis, DLQ02, including its potential benefits and a Phase 1b/2a clinical trial that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. You should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety, and efficacy of DLQ02, hyliQTM, or any of Dermaliq’s other product candidates, the potential benefits or applications of Dermaliq’s hyliQTM technology, Dermaliq’s ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of DLQ02 and other product candidates, and the timing the commencement of clinical trials, initial and ongoing data availability, and other development milestones.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dermaliq Therapeutics Inc.
Dr. Frank Loescher
Chief Executive Officer
Email: info@dermaliq.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lineage Logistics Strengthens Leadership Team, Appoints New Board Member and New Chief Legal Officer4.10.2022 21:57:00 EEST | Press release

Lineage Logistics, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced the appointment of Lynn Wentworth, a seasoned public board member, to its Board of Directors. Additionally, Lineage also announced the appointment of Natalie Matsler as Chief Legal Officer and Corporate Secretary. In this role, she will oversee Lineage’s global Legal, Safety & Compliance, Food Optimization and Corporate Compliance functions. Wentworth joins Lineage’s Board of Directors at a pivotal time in the Company’s growth. She brings deep expertise in finance, technology and logistics to Lineage’s board and currently serves on the boards of Graphic Packaging (NYSE: GPK), where she chairs the Compensation & Human Capital Committee, and Benchmark Electronics (NYSE: BHE), where she chairs the Audit Committee. She is the former Chairman of CyrusOne and Cincinnati Bell and chaired the Audit & Finance Commit

Lenovo Showcases How Smarter Technology is Empowering a Changing World at Tech World ‘224.10.2022 20:36:00 EEST | Press release

On October 18, 2022, Lenovo will host its annual global innovation event, Tech World, for the eighth consecutive year. This year’s virtual event will showcase how Lenovo's smarter technology is empowering people everywhere to change their world for the better. At Tech World ‘22, Lenovo will explore what’s next in our world, from the evolution of physical and virtual collaboration across users, spaces and devices, to how data creation is fueling the demand for computing everywhere. Tech World will feature a keynote session from Lenovo Chairman and CEO, Yuanqing Yang, who will present his insights on the possibilities smarter technology offers our changing world. Attendees will also hear from technology leaders and global CEOs who will show Lenovo’s innovation and partnership in action. Speakers include Lenovo’s SVP and Chief Technology Officer, Dr. Yong Rui; Accenture CEO, Julie Sweet; Chairman and CEO of IBM, Arvind Krishna; Intel CEO, Pat Gelsinger; and Qualcomm CEO, Cristiano Amon. L

 One Mind at Work, Columbia University Mental Health + Work Design Lab, and Ethisphere announce the Mental Health at Work Index™, the first of its kind comprehensive strategy to not only measure but also improve and innovate workplace mental health4.10.2022 19:00:00 EEST | Press release

One Mind at Work, a leading mental health non-profit, Columbia University Mental Health + Work Design Lab, and corporate ethical standards measurement company Ethisphere, have formed a partnership to develop the Mental Health at Work Index™. The Index includes a standardized assessment of organizational programs and practices that support workforce mental health and an advice library that provides recommendations and resources to guide data-driven strategic improvement and innovations. Accelerated by the COVID pandemic, around the world, the case for attending to mental health at work has never been greater. Research from the World Health Organization shows that 15 percent of working adults are affected by a mental health condition. The majority of workers expect their employers to support their mental health, and nearly all believe that employers could take actions that would make a real difference. Recognizing the importance of providing a standardized tool to help organizations of a

Andersen Global Expands Tax Capabilities in Canada4.10.2022 18:59:00 EEST | Press release

Andersen Global strengthens its Canadian presence through a Collaboration Agreement with Toronto-based tax firm Trowbridge Professional Corporation, further enhancing its seamless service capabilities in Canada. Managing Partners Todd Trowbridge, Arun (Ernie) Nagratha and Wayne Bewick founded the firm in 2002 after meeting during their time at Arthur Andersen. Trowbridge provides a broad range of international tax services, specializing in corporate tax, private clients and global mobility. Headquartered in Toronto, Trowbridge also has a presence in India, Germany and the UK. “Seamless service across all borders is central to our business model,” Ernie said. “Through this Collaboration Agreement with Andersen Global, our firm will have the support of a global organization, allowing us to maintain a competitive edge in the markets we serve.” “Our collaboration with Trowbridge broadens our tax capabilities by adding a key market to provide additional coverage in Canada,” said Andersen Gl

Mercans Adds Industry Veteran Steve Goldberg to its Board4.10.2022 17:07:00 EEST | Press release

Mercans, the global payroll technology leader, has announced that Steve Goldberg has joined its board as a non-executive director. The addition of an industry veteran to Mercans’ board follows several recently announced corporate governance changes to strengthen the board and executive management team of the global payroll and EOR service provider. When announcing Steve Goldberg’s appointment, Mercans’ board said, “We welcome Steve as a non-executive director to the board and believe that his long-term industry experience and insights will bring unique perspectives to Mercans. Steve’s strategic vision for the global payroll and HCM industry aligns well with Mercans’ strategy. We are confident that his leadership will further accelerate Mercans’ growth and strengthen its ability to deliver award-winning global payroll technology.” Steve Goldberg's 30+ year career on all sides of HR and Payroll technology includes HR executive roles across 3 continents, serving as HCM product strategy le

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom